5dgm
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==Crystal structure of human FPPS in complex with monophosphonate compound 7== | |
| + | <StructureSection load='5dgm' size='340' side='right' caption='[[5dgm]], [[Resolution|resolution]] 2.86Å' scene=''> | ||
| + | == Structural highlights == | ||
| + | <table><tr><td colspan='2'>[[5dgm]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5DGM OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5DGM FirstGlance]. <br> | ||
| + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=59Z:{2-[(PHOSPHONOMETHYL)CARBAMOYL]-1H-BENZO[G]INDOL-1-YL}ACETIC+ACID'>59Z</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene></td></tr> | ||
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5dgm FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5dgm OCA], [http://pdbe.org/5dgm PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5dgm RCSB], [http://www.ebi.ac.uk/pdbsum/5dgm PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5dgm ProSAT]</span></td></tr> | ||
| + | </table> | ||
| + | == Function == | ||
| + | [[http://www.uniprot.org/uniprot/FPPS_HUMAN FPPS_HUMAN]] Key enzyme in isoprenoid biosynthesis which catalyzes the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids, and ubiquinones. FPP also serves as substrate for protein farnesylation and geranylgeranylation. Catalyzes the sequential condensation of isopentenyl pyrophosphate with the allylic pyrophosphates, dimethylallyl pyrophosphate, and then with the resultant geranylpyrophosphate to the ultimate product farnesyl pyrophosphate. | ||
| + | <div style="background-color:#fffaf0;"> | ||
| + | == Publication Abstract from PubMed == | ||
| + | Targeting drugs to their desired site of action can increase their safety and efficacy. Bisphosphonates are prototypical examples of drugs targeted to bone. However, bisphosphonate bone affinity is often considered too strong and cannot be significantly modulated without losing activity on the enzymatic target, farnesyl pyrophosphate synthase (FPPS). Furthermore, bisphosphonate bone affinity comes at the expense of very low and variable oral bioavailability. FPPS inhibitors were developed with a monophosphonate as a bone-affinity tag that confers moderate affinity to bone, which can furthermore be tuned to the desired level, and the relationship between structure and bone affinity was evaluated by using an NMR-based bone-binding assay. The concept of targeting drugs to bone with moderate affinity, while retaining oral bioavailability, has broad application to a variety of other bone-targeted drugs. | ||
| - | + | A General Strategy for Targeting Drugs to Bone.,Jahnke W, Bold G, Marzinzik AL, Ofner S, Pelle X, Cotesta S, Bourgier E, Lehmann S, Henry C, Hemmig R, Stauffer F, Hartwieg JC, Green JR, Rondeau JM Angew Chem Int Ed Engl. 2015 Nov 23;54(48):14575-9. doi: 10.1002/anie.201507064. , Epub 2015 Oct 12. PMID:26457482<ref>PMID:26457482</ref> | |
| - | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
| - | + | </div> | |
| - | + | <div class="pdbe-citations 5dgm" style="background-color:#fffaf0;"></div> | |
| - | + | == References == | |
| + | <references/> | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
[[Category: Bourgier, E]] | [[Category: Bourgier, E]] | ||
| + | [[Category: Lehmann, S]] | ||
| + | [[Category: Rondeau, J M]] | ||
| + | [[Category: Cholesterol biosynthesis]] | ||
| + | [[Category: Isoprene biosynthesis]] | ||
| + | [[Category: Transferase]] | ||
Revision as of 11:43, 14 July 2016
Crystal structure of human FPPS in complex with monophosphonate compound 7
| |||||||||||
